ReviewFrontiers in microbiology2026
Mushroom-derived polysaccharides as broad-spectrum antimicrobial agents: mechanisms, structural modifications, and therapeutic potential.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance poses one of the most pressing threats to global public health, underscoring the urgent need for novel antimicrobial agents. Mushroom-derived polysaccharides have attracted considerable attention due to their structural diversity, low toxicity and various pharmacological activities. This review provides a comprehensive overview of the antiviral, antibacterial, and antifungal activities of polysaccharides isolated from edible and medicinal mushrooms against a range of pathogens, including multidrug-resistant species, with particular emphasis on the structural features that govern their efficacy. The mechanisms underlying these activities are examined, encompassing host immunomodulation, inhibition of pathogen attachment and entry, enzymatic inhibition of microbial replication and direct disruption of microbial cell integrity. Strategies to enhance antimicrobial potency are also discussed, covering chemical derivatization (e.g., sulfation, deacetylation), nanocomposite formulation and combination with conventional antimicrobials. Finally, the challenges of clinical translation including limited oral bioavailability, structural heterogeneity across preparations, and the lack of randomized clinical trial data in infectious disease indications, are critically evaluated. Addressing these gaps through standardization of production protocols, integrative structure-activity characterization and well-designed clinical trials will help advance the application of mushroom polysaccharides in medicine, food preservation, and agriculture.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.